BCD 700
Alternative Names: BCD-700Latest Information Update: 28 Jan 2021
At a glance
- Originator BIOCND
- Developer Pharma Research BIO
- Class Osteoporosis therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Osteoporosis
Most Recent Events
- 28 Jan 2021 No recent reports of development identified for research development in Osteoporosis in South Korea
- 16 Dec 2016 BIOCND plans to license BCD 700 (BIOCND pipeline, December 2016)
- 16 Dec 2016 Early research in Osteoporosis in South Korea (unspecified route)